Organon on June 3, 2021, launched the only global company focused on women’s health in Singapore. The company will focus on delivering impactful medicines and solutions for a healthier every day for women, their families and communities in Asia Pacific and by accelerating business in the region.

Organon’s diverse portfolio will consist of more than 60 medicines and products across an international footprint that serves people in more than 140 markets, with nearly 80% of its global US$6.5 billion in revenue generated outside the U.S. Organon believes it is well-positioned for organic low-to-mid-single digit growth from its 2021 base of business. Organon has three core pillars that will benefit from renewed management focus and commercial investment: women’s health, biosimilars and established brands.

The company’s extensive global capabilities in clinical development and patient safety, regulatory and medical affairs make it well-positioned to identify promising drugs, diagnostics and devices with the greatest potential to impact women’s health.

“We are very excited to launch Organon around the world. We build upon our strong foundation of more than 60 established medicines and solutions across a range of areas including reproductive health, heart disease, breast cancer, allergies, and asthma.” said Kaja Natland, the lead.

“With more than 2 billion people in this region, we are committed to making a world of difference in women's health every day. The diversity of our business provides an established portfolio so we can look to invest in and advance new medicines and solutions for women that are so urgently needed” added Andreas Jorgensen, Managing Director, South-East and Southeast Asia markets.

Organon Singapore Commercial Director Aman Sood, shared “We are thrilled that Organon has chosen Singapore as its head office for the Asia Pacific and Japan region. We are inspired to push past the limits of today and bring healthcare solutions to women and patients across the region.”